Pharmacology & Therapeutics

Papers
(The H4-Index of Pharmacology & Therapeutics is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue1167
Unfolded protein responses: Dynamic machinery in wound healing384
Exploiting the obesity-associated immune microenvironment for cancer therapeutics382
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption278
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications265
Editorial Board234
Collateral lethality: A unique type of synthetic lethality in cancers206
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis200
The role of macrophages in asthma-related fibrosis and remodelling179
Non-canonical G protein signaling177
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis171
Potential neonatal toxicity of new psychoactive substances162
Adenosine receptor signalling as a driver of pulmonary fibrosis151
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy143
Matrikines in the skin: Origin, effects, and therapeutic potential143
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target129
Endothelial dysfunction as a complication of anti-cancer therapy129
Inflammation, lipids, and pain in vulvar disease118
In cancer, all roads lead to NADPH117
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression115
Cell-based therapies for vascular regeneration: Past, present and future115
TLR4 biased small molecule modulators112
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy112
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance111
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions110
Boron in cancer therapeutics: An overview103
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches99
TAAR1 as an emerging target for the treatment of psychiatric disorders99
Contribution of non-selective membrane channels and receptors in epilepsy99
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives93
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved85
Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine85
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets84
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors84
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics83
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases83
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization80
Dysregulation of metabolic pathways in pulmonary fibrosis80
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases80
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond78
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?77
PGRMC1: An enigmatic heme-binding protein76
Pharmacological treatment of cardiogenic shock – A state of the art review75
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents75
Bispecific antibodies for the treatment of neuroblastoma74
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors73
Natural products that alleviate depression: The putative role of autophagy72
Review: Sex-related differences in the treatment of cardiac arrhythmia69
Editorial Board68
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]68
Wnt signaling: A prospective therapeutic target for chronic pain67
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance67
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease66
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy65
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms64
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?62
Stabilizing the neural barrier – A novel approach in pain therapy62
DNA methylation in cell plasticity and malignant transformation in liver diseases62
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression62
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy61
0.029764175415039